KR20100093786A - A method of manufacture for salt with ginseng, wormwood or eleutherococcus senticosus - Google Patents
A method of manufacture for salt with ginseng, wormwood or eleutherococcus senticosus Download PDFInfo
- Publication number
- KR20100093786A KR20100093786A KR1020090012874A KR20090012874A KR20100093786A KR 20100093786 A KR20100093786 A KR 20100093786A KR 1020090012874 A KR1020090012874 A KR 1020090012874A KR 20090012874 A KR20090012874 A KR 20090012874A KR 20100093786 A KR20100093786 A KR 20100093786A
- Authority
- KR
- South Korea
- Prior art keywords
- salt
- ginseng
- hours
- extract
- evaporate
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 87
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 70
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 63
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 62
- 235000003261 Artemisia vulgaris Nutrition 0.000 title claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 title claims abstract description 8
- 235000003097 Artemisia absinthium Nutrition 0.000 title claims abstract description 8
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 title claims abstract description 8
- 239000001138 artemisia absinthium Substances 0.000 title claims abstract description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 241000208340 Araliaceae Species 0.000 title claims abstract 12
- 240000001851 Artemisia dracunculus Species 0.000 title description 5
- 238000000034 method Methods 0.000 title description 5
- 241001632410 Eleutherococcus senticosus Species 0.000 title description 2
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 34
- 238000010438 heat treatment Methods 0.000 claims abstract description 30
- 239000000284 extract Substances 0.000 claims abstract description 22
- 238000001556 precipitation Methods 0.000 claims abstract description 22
- 239000003651 drinking water Substances 0.000 claims abstract description 10
- 235000020188 drinking water Nutrition 0.000 claims abstract description 10
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 4
- 125000000962 organic group Chemical group 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 15
- 239000004615 ingredient Substances 0.000 abstract description 12
- 206010063409 Acarodermatitis Diseases 0.000 abstract description 5
- 241000447727 Scabies Species 0.000 abstract description 5
- 208000005687 scabies Diseases 0.000 abstract description 5
- 239000006049 herbal material Substances 0.000 abstract description 3
- 235000008216 herbs Nutrition 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 235000005118 dietary health Nutrition 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 239000002244 precipitate Substances 0.000 abstract description 2
- 230000001376 precipitating effect Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 58
- 239000003814 drug Substances 0.000 description 11
- 235000002789 Panax ginseng Nutrition 0.000 description 10
- -1 glycoside saponin Chemical class 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229930182470 glycoside Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 230000001256 tonic effect Effects 0.000 description 6
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 6
- WXQYRBLGGSLJHA-UHFFFAOYSA-N Capillene Chemical compound CC#CC#CCC1=CC=CC=C1 WXQYRBLGGSLJHA-UHFFFAOYSA-N 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 235000004883 caffeic acid Nutrition 0.000 description 3
- 229940074360 caffeic acid Drugs 0.000 description 3
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 229940097217 cardiac glycoside Drugs 0.000 description 2
- 239000002368 cardiac glycoside Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 229930002534 steroid glycoside Natural products 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 229940119569 wormwood extract Drugs 0.000 description 2
- CMJGAYUQSLJSCR-WACFDSSMSA-N (-)-Hibalactone Natural products C1=C2OCOC2=CC(/C=C2/[C@@H](CC=3C=C4OCOC4=CC=3)COC2=O)=C1 CMJGAYUQSLJSCR-WACFDSSMSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010065420 Coronary artery dilatation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CMJGAYUQSLJSCR-UUASQNMZSA-N Isohabilactone Natural products C1=C2OCOC2=CC(/C=C2/C(CC=3C=C4OCOC4=CC=3)COC2=O)=C1 CMJGAYUQSLJSCR-UUASQNMZSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 235000003174 Panax japonicus Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- CMJGAYUQSLJSCR-UHFFFAOYSA-N hibalactone Natural products C1=C2OCOC2=CC(C=C2C(CC=3C=C4OCOC4=CC=3)COC2=O)=C1 CMJGAYUQSLJSCR-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- JGPMLTMSOKTANE-UHFFFAOYSA-N savinin Natural products O=C1OCC(/C/1=Cc2ccc3OCOc3c2)c4ccc5OCOc5c4 JGPMLTMSOKTANE-UHFFFAOYSA-N 0.000 description 1
- CMJGAYUQSLJSCR-ULIPXBITSA-N savinin Chemical compound C1=C2OCOC2=CC(\C=C2/[C@@H](CC=3C=C4OCOC4=CC=3)COC2=O)=C1 CMJGAYUQSLJSCR-ULIPXBITSA-N 0.000 description 1
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a method for producing ginseng, wormwood, and organo salts.
<Purpose>
Therefore, the technical gist of the present invention is to boil one of the ginseng, mugwort or scabies herbal medicine (medicinal herbs) at a set time and temperature, and then evaporate by precipitating the natural salt in the extracted extract extract. Roasted again with fire) is characterized in that the ingredients of the herbal ingredients soak in the salt itself to take the efficacy of ginseng, mugwort or agapi with salt at the same time.
<Composition>
In order to achieve the above object, the present invention puts ginseng 10 ~ 80% by weight in drinking water and extract the essence extract to boil at 80 ~ 90 ℃ for 24 hours (S100); 20 to 90% by weight of sun salt in the extracted ginseng extract, and then precipitated at room temperature for 10 hours, followed by a salt precipitation step (S200); A primary heating step (S300) of roasting ginseng and salt in a dried state at 500 to 600 ° C. for 2 to 3 hours after precipitation to evaporate moisture; The second heating step (S400) to fry the first heated ginseng and salt at 90 ~ 100 ℃ for 2 to 3 hours to evaporate the remaining moisture; It is constructed and manufactured.
<Effect>
As described above, the present invention boils ginseng, wormwood or agapi as a herbal material, precipitates the salt in the produced essence, and then evaporates and frys it again, so that the essence of the herbal component in the salt itself is not simply mixed or coated, but into the salt. It is formed to soak, while including the efficacy of the concentrated herbal ingredients as it is possible to eat at the same time with salt has a beneficial effect on dietary health.
Description
The present invention boils one of the herbal ingredients (medicinal herbs) of ginseng, wormwood or scabies at a set time and temperature, and then evaporates by precipitating the natural salt in the extracted extract liquid to high temperature (high heat) and medium temperature (low light). It relates to a manufacturing method of ginseng, mugwort, and sorghum salt by roasting the ingredients of the herbal ingredients soak in the salt itself to simultaneously consume the effects of ginseng, mugwort or agapi.
In general, humans contain as much salt as 0.9% of body fluids, but sodium in salts maintains the proper amount of fluids in the body, including blood, and balances acid and base. It helps to eat, and plays an important role when nerves send signals or muscles contract.
Thus, the minimum amount of sodium required by the human body is 10-20 mEq per day, which is contained in 5-10 g of salt.
On the other hand, the lack of sodium in the body causes serious symptoms. Especially, if the sodium deficiency progresses in a short time, brain cells swell, causing anorexia, nausea, vomiting, difficulty concentrating, confusion, lethargy, excitement, headache, and convulsions. Symptoms occur.
In other words, salt is an essential ingredient for maintaining good health as well as promoting metabolic smoothness.
Panax ginseng is a perennial herbaceous plant native to the northeastern Asia of Asia and is classified as genus Panax in the family Arboraceae or Ogalpiaceae. About 11 kinds of ginseng are known on the earth, and Korean ginseng (Panax ginseng CA Meyer) is native to the Far East of Asia (33 ~ 48 ° North: Korea, North Manchuria, Russia), and is very effective. Panax ginseng (Panax quinquefolium L.) grows and grows in the United States and Canada, Panax notoginseng FH Chen grows wild or grows in the southwestern region of Guangxi province in southeastern Yunnan Province, Panax japonicus CA Meyer in Japan and China. It is known to be distributed to southwestern and Nepal.
Ginseng is the best known nutritive tonic in both East and West, and it has been used as a commodity in the new agricultural plant and has been used as a valuable medicine since ancient times. Being explained.
Scientific research on the active ingredients of ginseng began in the late 19th century, and according to the development of organic chemistry, especially natural product chemistry, various kinds of medicinal ingredients have been separated and many of them have been identified.
Many pharmacological experiments to date have revealed that ginseng strengthens the nonspecific resistance of the body to stress and has an acidic action.
In addition, hypertension, insulin action, hypoglycemic effect in alloxan diabetic mice, liver RNA synthesis in rats, protein synthesis, sugar and lipid metabolism promoting effect, anti-cancer effect, hyperlipidemia, etc. .
In addition, ginseng has an excellent effect as a tonic, and it has effects of fatigue recovery and physical strength improvement, arteriosclerosis prevention, diabetes treatment effect, anti-inflammatory and anti-tumor effect, adult disease prevention, anti-aging effect, tonic effect Inhibit menopausal disorders, antioxidant effects, liver function protection, anticancer activity, antistress effect, immunity enhancement, thrombus improvement, brain function improvement, brain cell protection, etc. Can be.
The ginseng has been used for various diseases such as psychiatric diseases, nervous system diseases and diabetes in the form of herbal medicine mainly in Asian countries such as Korea, China and Japan, and saponins, the main components of the ginseng, are tonic, gangjeong, soothing It is known to show effects on hematopoiesis and antihypertension.
This ginseng is used in the form of red ginseng, which is produced by heating white ginseng or ginseng as it is grown and harvested at room temperature, at 98 to 100 ° C., or ginseng prepared by heating at 120 to 180 ° C.
Ginseng saponins such as ginsenosides Rb1, Rb2, and Rc, which are the main components of ginseng, can be mentioned. Saponins are mainly triterpene glycosides composed of dammarane-based aglycosides and several different numbers of sugars. And about 40 kinds are found in the ground.
On the other hand, among these ginseng, Korean ginseng has been used in traditional medicine as an antidiabetic medicine, and modern medicine has been confirmed for its efficacy against diabetes.
For example, animal experiments using hypoglycemic components (DPG 3-2) isolated from ginseng confirmed that the component had a function of promoting insulin secretion (Kimura, 3rd International Ginseng Symposium, 1980), diabetes Clinical trials of red ginseng in patients showed that blood glucose levels were lowered and the dose reduction was controlled in patients treated with insulin, especially subjective symptoms such as dizziness, stiff shoulders, chest compressions, thirst, general malaise, and heavy head. Symptoms were greatly improved (Jo Joon-seung, et al., Understanding Korean Ginseng, 1995, 20).
Korean ginseng has been called a mysterious medicine for thousands of years and has been widely used for the prevention and treatment of various diseases. Former Soviet pharmacologist Dr. Brekhman wrote a book called Ginseng in 1975 to summarize the results of pharmacological, biological and chemical research on ginseng. Ginseng has a tonic effect, fatigue prevention effect, improved work efficiency, and excitement and sedation of the central nervous system. This is due to the glycoside saponin component contained in ginseng, thus preparing new electricity for ginseng. Ginseng glycoside saponin has been found to contain ingredients that have effects such as anti-cancer, fatigue recovery, antioxidant, anti-diabetic, anti-inflammatory and hematopoietic function.
In addition, the herbal herb (本草綱目) has described the efficacy of ginseng relatively broadly, and today ginseng is used in various clinical symptoms based on this.
In addition, many Chinese medicine describes the efficacy and prescription examples of ginseng, and ginseng is a medicinal herb that plays a central role in prescription.
Oral medicine is a medicine that is taken not only to get sick, but also to maintain health as a normal drug means a drug that is harmless and does not hurt a person even when taken in large amounts or for a long time.
On the other hand, wormwood is an edible perennial herb that grows naturally from spring throughout Korea, and has a bitter bitter taste but has no odor and has a light taste.
The ground part of Artemisiae Capillaris Thumberg is called Injin mugwort. When it grows about 6 ~ 10cm in spring, the can is called cotton injin and when the buds grow long in the autumn, the stem is harvested. Removed and healthy is called Injinho (하고 陳 蒿).
Thus, the jinjamyeo Capillene (Capillene), Keppelin (Capilline), Keplon (Cappillone), Folic acid (Folic acid), Caffeic acid (Caffeic acid), Dimethyl aesculetin (Polyphenol), Polyphenol (Polyphenol) And other components are contained.
According to oriental medicine, mugwort is antipyretic, edema, antibacterial, antiviral, antifungal, lipid-enhanced (serum) It is known to have a function of preventing cholesterol deposition on blood vessel walls by lowering cholesterol and β-lipoprotein, and a fungicide.
On the other hand, dimethyl ascuretine and caffeic acid contained in mugwort have an Idam effect, and kephilin and polyphenol have antibacterial, antiviral, and antifungal effects. Mugwort has anti-oxidation and deodorization functions in addition to the above-mentioned effects It is known to have.
In addition, Ogapi is a deciduous broad-leaved shrub belonging to the Armenaceae family, such as ginseng, and its scientific name is called acanthopanax. It has been used in many medicines because it has an effect on metabolic promoting muscle strengthening detoxification and the like.
In particular, the root contains lignans such as sesamin, savinin, and arkanside B and D, and components such as eoterosideside A, cardiac glycoside (glutoside), and saponin, and other water-soluble polysaccharides such as glucan and alkaline polysaccharides. When alkaline polysaccharides are decomposed into water, anti-lactose aldehyde, glucose, arabian acid, suricose, and wood sugar are made. The root contains polysaccharide glycosides (0.6 ~ 0.9%), including carotenesterol, 7 -Hydroxyl group (hydroxyl group) -6, 8-2 sudden aromatic parrot, α-glucose glucoside, group α-anti-glucose glucoside, sirgaresinol glucose glucoside, and sirin. In addition, the phase contains sesamin and polysaccharides (2,3 to 5.7%), and the stem contains glycoside glycosides of 0.6 to 15%.
In addition, the leaves and stems of Ogapi contain 0.228% of cardiac glycosides, 0.1% of volatile oils, and saponins, and the leaves of Zhaoga contain eoterosides.
Therefore, ginseng root and stem have a similar effect to ginseng, the main component is triterpenoid glycosides 7 types are identified and named eoteoroside A ~ G, other bioactive components are sterol, coumarin (blood pressure Lowering, sedation), sirin (anti-fatigue, excitatory), sesamin (coughing), and hyperferin (coronary artery dilatation) are included to increase central nervous system excitability, tonic action, and nonspecific resistance of the organism. Actions, tendons and bones to strengthen the action, such as when you can not use the legs, arms and legs when you use a good effect.
In addition, it eliminates the customs (Wind), 기 (기) to strengthen the bones and tendons, the treatment of fragile edema or various paralysis symptoms and various symptoms caused by the reproductive weakness.
The present invention is to solve the above problems, the technical gist of any one herbal material (medicinal herbs) of ginseng, mugwort or scabies after boiling at a set time and temperature to precipitate and evaporate the natural salt in the extracted extract liquid Ginseng, mugwort, and scabies can be ingested at the same time as the effects of ginseng, mugwort or agapi by roasting again at high temperatures (high heat) and medium temperature (weak fire) so that the ingredients of the herbal ingredients infiltrate the salt itself. Its purpose is to provide a method for preparing salt.
In order to achieve the above object, the present invention is to prepare a ginseng salt, mugwort salt or agaga salt by mixing the natural salt in the extract extracted from ginseng, mugwort or agar,
Thus, the ginseng salt is put into 10 ~ 80% by weight of ginseng in drinking water extracts boiled at 80 ~ 90 ℃ for 24 hours to extract the essence (S100) and; 20 to 90% by weight of sun salt in the extracted ginseng extract, and then precipitated at room temperature for 10 hours, followed by a salt precipitation step (S200); A primary heating step (S300) of roasting ginseng and salt in a dried state at 500 to 600 ° C. for 2 to 3 hours after precipitation to evaporate moisture; The second heating step (S400) to fry the first heated ginseng and salt at 90 ~ 100 ℃ for 2 to 3 hours to evaporate the remaining moisture; It is constructed and manufactured.
In addition, the mugwort salt is wormwood extract step (S100-1) formed by putting 10 ~ 80% by weight in mugwort to boil at 80 ~ 90 ℃ for 24 hours to extract the essence; A salt precipitation step (S200-2) in which 20 to 90% by weight of sun salt is added to the extracted mugwort extract and precipitated at room temperature for 10 hours, followed by drying; A primary heating step (S300-3) to fry the dried mugwort and salt in 500 to 600 ° C. for 2 to 3 hours after precipitation to evaporate the moisture; The secondary heating step (S400-4) to fry the first heated mugwort and salt at 90 ~ 100 ℃ for 2 to 3 hours to evaporate the remaining moisture; It is constructed and manufactured.
In addition, Ogapi salt is put in 10 ~ 80% by weight of Ogapi in drinking water extracts boiled at 80 ~ 90 ℃ for 24 hours to extract the essence extract (S100-10); A salt precipitation step (S200-20) in which 20 to 90% by weight of sun salt is added to the extracted Ogapi essence and precipitated at room temperature for 10 hours; A primary heating step (S300-30) to simmer the dried Ogapi and salt at 500 to 600 ° C. for 2-3 hours after precipitation to evaporate the moisture; A second heating step (S400-40) to fry the first heated organopi and salt at 90 to 100 ° C. for 2 to 3 hours to allow residual moisture to evaporate; It is constructed and manufactured.
Therefore, the present invention is boiled ginseng, wormwood or agai as a herbal material precipitates the natural salt in the produced essence and then evaporated and roasted again, the essence of the herbal components in the salt itself is not simply mixed or coated, but into the salt Formed to soak, it is possible to eat at the same time as the salt while containing the efficacy of the concentrated herbal ingredients as it has a beneficial effect on dietary health.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described in detail below with reference to the accompanying drawings.
As shown in Figures 1 to 3, the present invention is to prepare the ginseng salt, mugwort salt or organo salts by mixing the natural salt in the extract extracted from ginseng, mugwort or agar.
Thus, the ginseng salt is put into 10 ~ 80% by weight of ginseng in drinking water extracts boiled at 80 ~ 90 ℃ for 24 hours to extract the essence (S100) and; 20 to 90% by weight of sun salt in the extracted ginseng extract, and then precipitated at room temperature for 10 hours, followed by a salt precipitation step (S200); A primary heating step (S300) of roasting ginseng and salt in a dried state at 500 to 600 ° C. for 2 to 3 hours after precipitation to evaporate moisture; The second heating step (S400) to fry the first heated ginseng and salt at 90 ~ 100 ℃ for 2 to 3 hours to evaporate the remaining moisture; It is constructed and manufactured.
At this time, the ginseng is preferably Korean ginseng, it is preferable to evaporate at room temperature in the shade when drying after drying the natural salt in the essence.
At this time, the primary heating step is preferably put in the barrel rotating impeller by the motor so that the salt precipitated in the essence is not attached to the hardened to be heated during low speed rotation at 10 ~ 50rpm.
In addition, it is preferable to dry naturally at room temperature after the second heating step.
On the other hand, the mugwort salt is wormwood extract step (S100-1) formed by putting 10 ~ 80% by weight in the drinking water to boil at 80 ~ 90 ℃ for 24 hours to extract the essence; A salt precipitation step (S200-2) in which 20 to 90% by weight of sun salt is added to the extracted mugwort extract and precipitated at room temperature for 10 hours, followed by drying; A primary heating step (S300-3) to fry the dried mugwort and salt in 500 to 600 ° C. for 2 to 3 hours after precipitation to evaporate the moisture; The secondary heating step (S400-4) to fry the first heated mugwort and salt at 90 ~ 100 ℃ for 2 to 3 hours to evaporate the remaining moisture; It is constructed and manufactured.
At this time, it is preferable that the mugwort is phosphorus mugwort, and evaporate at room temperature in the shade at the time of drying after precipitation of sun salt in the essence.
At this time, the primary heating step is preferably put in the barrel rotating impeller by the motor so that the salt precipitated in the essence is not attached to the hardened to be heated during low speed rotation at 10 ~ 50rpm.
In addition, it is preferable to dry naturally at room temperature after the secondary heating step.
In addition, Ogapi salt is put in 10 ~ 80% by weight of Ogapi in drinking water extracts boiled at 80 ~ 90 ℃ for 24 hours to extract the essence extract (S100-10); A salt precipitation step (S200-20), in which 20 to 90% by weight of sun salt is added to the extracted Ogapi solution and precipitated at room temperature for 10 hours, followed by drying; A primary heating step (S300-30) to simmer the dried Ogapi and salt at 500 to 600 ° C. for 2-3 hours after precipitation to evaporate the moisture; A second heating step (S400-40) to fry the first heated organopi and salt at 90 to 100 ° C. for 2 to 3 hours to allow residual moisture to evaporate; It is constructed and manufactured.
At this time, it is preferable that the scabies are washed in clean drinking water, and evaporated at room temperature in the shade when dried after precipitation of sun salt in the essence.
At this time, the primary heating step is preferably put in the barrel rotating impeller by the motor so that the salt precipitated in the essence is not attached to the hardened to be heated during low speed rotation at 10 ~ 50rpm.
In addition, it is preferable to dry naturally at room temperature after the secondary heating step.
The present invention is not limited to the above-described specific preferred embodiments, and various modifications can be made by any person having ordinary skill in the art without departing from the gist of the present invention claimed in the claims. Of course, such changes will fall within the scope of the claims.
1 is an embodiment according to the present invention, a process block diagram for manufacturing ginseng salt,
Figure 2 is an embodiment according to the present invention, a block diagram of manufacturing a mugwort salt,
Figure 3 is an embodiment according to the present invention, a block diagram of a process for producing the organopige salt.
<Description of Symbols for Main Parts of Drawings>
S100 ... essence extraction step S200 ... sedimentation step
S300 ... first heating step S400 ... second heating step
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090012874A KR20100093786A (en) | 2009-02-17 | 2009-02-17 | A method of manufacture for salt with ginseng, wormwood or eleutherococcus senticosus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090012874A KR20100093786A (en) | 2009-02-17 | 2009-02-17 | A method of manufacture for salt with ginseng, wormwood or eleutherococcus senticosus |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20100093786A true KR20100093786A (en) | 2010-08-26 |
Family
ID=42758049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090012874A KR20100093786A (en) | 2009-02-17 | 2009-02-17 | A method of manufacture for salt with ginseng, wormwood or eleutherococcus senticosus |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20100093786A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101226528B1 (en) * | 2011-02-14 | 2013-02-13 | 생산자단체 황토천일염영농조합법인 | Process for Preparing natural salt containing plant ingredient |
KR101253041B1 (en) * | 2010-12-03 | 2013-04-10 | 송인상 | Manufacturing method of processed salt using medicinal plant |
KR20150137371A (en) * | 2014-05-29 | 2015-12-09 | 농업회사법인 (주) 미예당 | Manufacturing method of ginseng-salt for underground tunnel-jeotgal and ginseng-salt thereof |
CN111264833A (en) * | 2020-02-27 | 2020-06-12 | 福建师范大学泉港石化研究院 | Iodine salt for balancing and building body and preparation method thereof |
-
2009
- 2009-02-17 KR KR1020090012874A patent/KR20100093786A/en not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101253041B1 (en) * | 2010-12-03 | 2013-04-10 | 송인상 | Manufacturing method of processed salt using medicinal plant |
KR101226528B1 (en) * | 2011-02-14 | 2013-02-13 | 생산자단체 황토천일염영농조합법인 | Process for Preparing natural salt containing plant ingredient |
KR20150137371A (en) * | 2014-05-29 | 2015-12-09 | 농업회사법인 (주) 미예당 | Manufacturing method of ginseng-salt for underground tunnel-jeotgal and ginseng-salt thereof |
CN111264833A (en) * | 2020-02-27 | 2020-06-12 | 福建师范大学泉港石化研究院 | Iodine salt for balancing and building body and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104982599A (en) | Botanic herbal tea concentrate and low-sugar botanic herbal tea beverage | |
CN103493941A (en) | Weight-reducing and health-protecting tea and preparation method thereof | |
CN102380051A (en) | Medicinal steamed bread for treating diabetes | |
CN101366519B (en) | Hippophae rhamnoides flavone nourishing tea/powder and preparation process | |
CN103735897A (en) | Traditional Chinese medicine oral liquid for lowering blood pressure and regulating blood fat and preparation method thereof | |
CN107156828A (en) | A kind of full nutrition formula food suitable for patients with inflammatory bowel | |
CN104904936A (en) | A blood pressure and blood lipid lowering health-care tea and preparation method thereof | |
CN112336815A (en) | Anti-aging composition for strengthening body, preventing cancer and conditioning hypertension, hyperglycemia and hyperlipidemia and application thereof | |
CN107751993A (en) | A kind of antifatigue cream taste and preparation method thereof | |
KR20100093786A (en) | A method of manufacture for salt with ginseng, wormwood or eleutherococcus senticosus | |
KR20090021644A (en) | A carbohydrate and lipid absorption inhibitory nelumbo composition and its manufacturing process thereof | |
CN107233599B (en) | Air purifying agent capable of quickly removing metal pollutants in air | |
CN102604750A (en) | Method for preparing forest herbaceous plant biomass detergent | |
CN104644759A (en) | Health tea for preventing and/or treating influenza and preparation method thereof | |
CN108576325A (en) | A kind of function tea for treating enteritis | |
CN104472797A (en) | Herb tea capable of lowering blood pressure and preparation method thereof | |
CN101062283B (en) | Tea for reducing blood sugar and its preparing method | |
CN102754828A (en) | Health care oral liquid | |
CN102823698A (en) | Preparation method of composite notoginseng and black garlic filled chocolate | |
CN113652461A (en) | Preparation method of polygonatum sibiricum phytosterol polysaccharide protein and active product thereof | |
CN110522798A (en) | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease | |
CN104472755A (en) | Herb tea capable of lowering hyperlipidemia and preparation method thereof | |
CN102823699A (en) | Preparation method of composite ganoderma lucidum and black garlic filled chocolate | |
CN114558051B (en) | Chinese medicinal composition for treating diabetes and preparation method thereof | |
CN102823705A (en) | Preparation method of compound barbary wolfberry fruit and black garlic filled chocolate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |